Open AccessZnaczenie badań farmakogenetycznych w efektywności leczenia metotreksatem chorych na reumatoidalne zapalenie stawów (część 2)
Author(s) -
Jerzy Świerkot,
Ryszard Slęzak
Publication year - 2011
Publication title -
postępy higieny i medycyny doświadczalnej
Language(s) - Polish
Resource type - Journals
SCImago Journal Rank - 0.275
H-Index - 34
eISSN - 1732-2693
pISSN - 0032-5449
DOI - 10.5604/17322693.936691
Subject(s) - rheumatoid arthritis , methotrexate , medicine , adverse effect , pharmacogenetics , methylenetetrahydrofolate reductase , oncology , genotype , gene , genetics , biology
Much hope is currently associated with individualization of therapy provided to rheumatoid arthritis (RA) patients. The search is underway for biochemical and clinical markers that would be useful in prediction of a good response to methotrexate (MTX) therapy. Along with clinical factors, genetic predisposition may also be helpful. Polymorphism of genes participating in MTX metabolism may affect the drug’s efficacy and the rate of adverse effects. Pharmacogenetic studies may contribute to more effective individualization of therapy for RA patients. The purpose of the study was to determine the significance of gene polymorphisms MTHFR C677T and A1298C for efficacy of MTX therapy in RA patients. Patients possessing determined polymorphisms should be particularly carefully evaluated because of a higher risk of occurrence of adverse effects.